Xiuping Yu

This study identifies INSM1 as a key regulator of neuroendocrine plasticity and tumor progression in prostate cancer, showing its role in lineage programs and identifying HHT as a potential therapeutic agent.

This study identifies MYCL as a key driver of neuroendocrine lineage programs in prostate cancer by showing its upregulation in NEPC and its role in suppressing AR signaling and inducing neuroendocrine reprogramming.

This study identifies TET2 activation in slow-cycling cells as a driver of prostate cancer progression through epigenetic changes and shows targeting TET2 suppresses tumor growth.

This study investigates Wnt/beta-Catenin signaling in neuroendocrine prostate cancer, finding elevated pathway activity and potential therapeutic targeting.

This study investigates AR-driven gene expression and epigenetic changes in prostate cancer using multi-omics data from LNCaP cells, identifying gene expression shifts and AR binding patterns under androgen deprivation therapy.

This study identifies α-synuclein's role in regulating inflammatory gene expression in melanoma cells through RNA sequencing and validation.

This study examines PKM1 and PKM2 expression in mouse and human prostatic tissues across development, benign, and cancerous states, revealing distinct patterns in PCa and NEPCa.

PCTA provides a curated pan-cancer cell line transcriptome atlas with user-friendly tools for gene expression analysis across diverse cancer types.